公开(公告)号：US20190134058A1

公开(公告)日：2019-05-09

申请号：US16095917

申请日：2017-05-04

Applicant: Mithra Pharmaceuticals S.A.

Inventor： Séverine JASPART

IPC: A61K31/56 ,  A61K9/20

CPC classification number: A61K31/56 ,  A61K9/2018 ,  A61K9/2059 ,  A61K31/567

Abstract: A method of stabilizing tibolone in a solid dosage form using a sugar-alcohol, and a pharmaceutical composition, in particular a solid dosage form such as a tablet, including tibolone, a sugar-alcohol and a non-sugar-alcohol diluent. The weight ratio of the sugar-alcohol to the non-sugar-alcohol diluent is between 4:1 and 1:4.

公开(公告)号：US20180338962A1

公开(公告)日：2018-11-29

申请号：US16047008

申请日：2018-07-27

Applicant: Infinity Pharmaceuticals, Inc.

Inventor： Alfredo C. Castro ,  Michael J. Grogan ,  Karen J. McGovern ,  Martin R. Tremblay

IPC: A61K31/4355 ,  C07D471/10 ,  A61K31/58 ,  C07D307/94 ,  A61K45/06 ,  C07D491/107 ,  A61K38/21 ,  A61K31/7076 ,  A61K31/7068 ,  A61K31/704 ,  A61K31/69 ,  A61K31/664 ,  A61K31/573 ,  A61K31/56 ,  A61K31/519 ,  A61K31/4745 ,  A61K31/454 ,  A61K31/198 ,  A61K31/196 ,  A61K31/17 ,  C07D491/048 ,  A61N5/10 ,  A61K9/00 ,  C07J69/00 ,  C07D491/10 ,  C07D491/04 ,  C07D471/04

CPC classification number: A61K31/4355 ,  A61K9/0014 ,  A61K31/17 ,  A61K31/196 ,  A61K31/198 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/519 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K31/664 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/7076 ,  A61K38/21 ,  A61K45/06 ,  A61N5/10 ,  C07D307/94 ,  C07D471/04 ,  C07D471/10 ,  C07D491/04 ,  C07D491/048 ,  C07D491/10 ,  C07D491/107 ,  C07J69/00

Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:

公开(公告)号：US20180311193A1

公开(公告)日：2018-11-01

申请号：US16020517

申请日：2018-06-27

Applicant: KUWAIT UNIVERSITY

Inventor： MILAD S. BITAR ,  FAHD AL-MULLA

IPC: A61K31/19 ,  A61K31/56 ,  C12N15/113

CPC classification number: A61K31/19 ,  A61K31/56 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/3233

Abstract: The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18α-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

公开(公告)号：US20180303869A1

公开(公告)日：2018-10-25

申请号：US15823996

申请日：2017-11-28

Applicant: Clarus CLS Holdings, LLC

Inventor： C. Michael SAMSON ,  Bo LIANG ,  Joseph A. CAPRIOTTI

IPC: A61K31/79 ,  A61K47/38 ,  A61K9/00 ,  A61K47/34 ,  A61K47/02 ,  A61K31/24 ,  A61K33/18 ,  A61K31/80 ,  A61K31/407 ,  A61K31/245 ,  A61K47/18 ,  A61K31/192 ,  A61K31/196 ,  A61K31/4535 ,  A61K31/56 ,  A61K31/573 ,  A61K45/06

CPC classification number: A61K31/79 ,  A61K9/0048 ,  A61K31/192 ,  A61K31/196 ,  A61K31/24 ,  A61K31/245 ,  A61K31/407 ,  A61K31/4535 ,  A61K31/56 ,  A61K31/573 ,  A61K31/80 ,  A61K33/18 ,  A61K45/06 ,  A61K47/02 ,  A61K47/183 ,  A61K47/34 ,  A61K47/38 ,  A61K2300/00

Abstract: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.

公开(公告)号：US20180271879A1

公开(公告)日：2018-09-27

申请号：US15676102

申请日：2017-08-14

Applicant: NATIONAL DONG HWA UNIVERSITY

Inventor： Mei-Chin Lu ,  Ping-Jyun Sung ,  Jui-Hsin Su ,  Kuei-Hung Lai ,  Yi-Chang Liu ,  Ying-Chi Du ,  Yu-Ming Hsu ,  Ming-Kai Weng ,  Fu-Wen Kuo

IPC: A61K31/56 ,  A61K31/122 ,  A61K35/655

CPC classification number: A61K31/56 ,  A61K31/122 ,  A61K35/655

Abstract: The present invention discloses scalarane sesterterpenoids represented by formula (I) and meroditerpenoid represented by formula (II), which are extracted from Carteriospongia sp. sponge: where R1 is —CH3 or —C2H5. The compounds of formula (I) can be used to be an anticancer, act as an inhibitor targeting to topoisomerase II and hsp90 and a pharmaceutical composition for anticancer.

公开(公告)号：US20180264107A1

公开(公告)日：2018-09-20

申请号：US15982823

申请日：2018-05-17

Applicant: Genentech, Inc. ,  Biogen Inc.

Inventor： John G. Curd ,  Antonio J. Grillo-Lopez ,  Lori A. Kunkel

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/365 ,  A61K31/56 ,  A61K45/06 ,  A61K47/68 ,  A61K51/10

CPC classification number: A61K39/3955 ,  A61K31/365 ,  A61K31/56 ,  A61K45/06 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  A61K2039/54 ,  C07K16/2803 ,  C07K16/2887 ,  C07K2317/24 ,  Y10S424/801 ,  Y10S424/81

Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.

公开(公告)号：US20180264006A1

公开(公告)日：2018-09-20

申请号：US15761759

申请日：2016-09-22

Applicant: REGENERA PHARMA LTD.

Inventor： Zadik HAZAN ,  Konstantin ADAMSKY ,  Andre C. B. LUCASSEN ,  Nurit NOVAK

IPC: A61K31/56 ,  A61K31/569 ,  A61K31/122 ,  A61K36/22

CPC classification number: A61K31/56 ,  A61K31/122 ,  A61K31/569 ,  A61K31/575 ,  A61K31/745 ,  A61K36/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating for use in treating a condition selected from Alzheimer's disease (AD), Parkinson's Diseases (PD) and vascular dementia (VD).

公开(公告)号：US20180256603A1

公开(公告)日：2018-09-13

申请号：US15761755

申请日：2016-09-22

Applicant: REGENERA PHARMA LTD.

Inventor： Zadik HAZAN ,  Konstantin ADAMSKY ,  Andre C. B. LUCASSEN ,  Nurit NOVAK

IPC: A61K31/575 ,  A61K31/56 ,  A61K31/047 ,  A61K31/122 ,  A61P9/10

CPC classification number: A61K31/575 ,  A61K31/047 ,  A61K31/122 ,  A61K31/56 ,  A61K31/569 ,  A61K31/745 ,  A61K36/22 ,  A61K45/06 ,  A61P9/10 ,  A61K2300/00

Abstract: The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating stroke or trauma and side effects related thereto.

公开(公告)号：US20180256507A1

公开(公告)日：2018-09-13

申请号：US15975577

申请日：2018-05-09

Applicant: Eupraxia Pharmaceuticals USA LLC

Inventor： James A. Helliwell ,  Amanda M. Malone ,  Thomas J. Smith ,  Marc M. Baum

IPC: A61K9/50 ,  A61K31/58 ,  A61K31/56 ,  A61K9/00

CPC classification number: A61K9/5026 ,  A61K9/0024 ,  A61K31/56 ,  A61K31/58

Abstract: Described herein are injectable corticosteroid-loaded microparticles, pharmaceutical composition thereof and methods for reducing inflammation or pain in a body compartment such as a joint, an epidural space, a vitreous body of an eye, a surgically created space, or a space adjacent to an implant.

公开(公告)号：US20180250224A1

公开(公告)日：2018-09-06

申请号：US15512147

申请日：2015-09-18

Applicant: Oxular Limited

Inventor： Ronald K. Yamamoto ,  Stanley R. Conston ,  Tien Nguyen

IPC: A61K9/00 ,  A61K31/573 ,  A61K9/16 ,  A61K31/436 ,  A61K31/7052

CPC classification number: A61K9/0051 ,  A61F9/0017 ,  A61K9/1647 ,  A61K31/436 ,  A61K31/56 ,  A61K31/573 ,  A61K31/7052 ,  A61K31/7105 ,  A61K47/32 ,  A61K47/34 ,  A61M2005/3267

Abstract: The present invention provides a composition for treatment of ophthalmic disease comprising a solid or semi-solid containing drug shaped as an elongated body for injection or delivery into tissue spaces of the eye. The composition may comprise a plurality of drug-containing particles and at least one excipient to form the drug particles into a flexible solid or a semisolid. The excipient comprises a substance that undergoes dissolution in the physiological conditions of the tissue space after injection to allow the microspheres to disperse and migrate in the tissue space. Formulations for the drug containing compositions, methods of fabrication and methods of use are also disclosed.